Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis

Mary L. Bowman, Michele Bergmann, James F. Smith

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Maternal thyrotoxicosis complicates approximately 0.2% of pregnancies. Simultaneous occurrence of maternal and fetal thyrotoxicosis during labor is rare, and control of maternal tachycardia and hypertension, as well as fetal manifestations of thyrotoxicosis, are cornerstones of management. An 18- year-old nulliparous female at 33 weeks gestational age presented in labor with thyrotoxicosis. Fetal tachycardia was present as well. Labetalol therapy resulted in a decrease in maternal pulse and blood pressure, and resolution of fetal tachycardia. Vaginal delivery occurred. Subsequent evaluation demonstrated neonatal thyrotoxicosis and high maternal titers of thyroid- stimulating immunoglobulin. In conclusion, labetalol was beneficial in the treatment of maternal and fetal thyrotoxicosis during labor.

Original languageEnglish (US)
Pages (from-to)795-796
Number of pages2
JournalThyroid
Volume8
Issue number9
DOIs
StatePublished - Jan 1 1998

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Intrapartum labetalol for the treatment of maternal and fetal thyrotoxicosis'. Together they form a unique fingerprint.

  • Cite this